SHANGHAI , June 24, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals, a biological high-tech enterprise focusing on R&D and services of innovative antibody drugs, and Dragon Sail Pharmaceutical, a CDMO and CMO enterprise dedicated to providing world-leading high-end biological drug manufacture services, announced a long-term strategic partnership taking effective. The two parties will share their experiences and technical advantages, and provide integrated and modular solutions that cover biological drug R&D, CDMO and commercial productions to the global biopharmaceutical industry.
Aiming to provide the pharmaceutical and biotechnology companies with high-quality, high-efficiency and cost-effective drug development and manufacturing services, the two companies will invest their advantageous resources, expertise and experience through this strategic partnership to carry out extensive collaboration in the field of drug discovery, drug development and CDMO. Sanyou will provide preclinical R&D services including drug screening, pharmacology research, process development and quality control of various biological drugs including monoclonal antibodies, multi-specific antibodies, ADC drugs, etc. Dragon Sail will provide services of pilot production, clinical sample production, scale-up process development and commercial production of various biological drugs.
Dragon Sail Pharmaceutical is a leading high-tech CDMO enterprise for biological drug production in China , committed to provide one-stop R&D and manufacturing outsourcing services from sequence to IND, and from clinical sample production to BLA and commercial production. With a total investment of 690 million RMB and a total production scale of up to 12000L, the company site is built and operated in compliance with NMPA and FDA cGMP requirements and has passed the EU QP audit, which qualifies for different stages of clinical sample and commercial drug productions. The company has a professional technical team of over 200 staffs, with team members from well-known domestic and international pharmaceutical companies and universities. 90% of the current employees are technical R&D professionals, and about 40% of the employees own master and doctoral degrees. Equipped with the advanced NONCROS® non-crossover antibody production technology, Dragon Sail has provided high quality and efficient R&D and manufacturing services to more than 10 pharmaceutical companies for various biological drug projects.
Sanyou Biopharmaceuticals is a biological high-tech company focusing on R&D and services of innovative antibody drugs. Sanyou has established an integrated innovative antibody drug R&D laboratory of more than 20,000 square meters with advanced facilities in Shanghai Caohejing High-Tech Park. Driven by the excellent innovation platforms of Super-Trillion Innovative Antibody Drug Discovery Platform, Integrated Innovative Antibody Drug R&D Platform and Intelligent Innovative Antibody Drug R&D Platform, Sanyou has 10 major functional modules and more than 40 core technological platforms covering preclinical R&D, and has a professional team of more than 250 staffs, over 70% of which holds a doctoral or master's degree. Sanyou has provided high quality and high efficiency innovative antibody drug development solutions, staged services and collaborative R&D to more than 300 companies and organizations worldwide, and several drug development projects above have entered the clinical stages.
"We are honored to deepen and broaden our collaboration with Sanyou" said Kai Tan , general manager of Dragon Sail Pharmaceutical. "Sanyou has accumulated a lot of successful experience in the discovery and development of antibody drugs. Dragon Sail Pharmaceutical has established a GMP-compliant cross-free manufacturing base in the new Lingang District and has built a systematic development platform for antibody drugs from DNA to BLA. The collaboration between the two parties will provide a powerful engine for successful antibody drug development, accelerate the new drug development process, empower partners and benefit more patients."
"We highly value our strategic partnership with Dragon Sail Pharmaceutical." said Guojun Lang , CEO of Sanyou Biopharmaceuticals. "Dragon Sail's robust antibody drug CMC development and GMP manufacturing platform has been recognized by the industry. Sanyou has excellent innovative drug discovery and preclinical R&D capabilities, and our proprietary super-trillion innovative antibody drug discovery platform integrates nine types of super-trillion innovative antibody libraries with a cumulative library capacity of up to ten trillion, and a high-throughput automated screening system. Sanyou will combine the technical advantages with Dragon Sail Pharmaceutical to provide more comprehensive and high quality one-stop services to our clients."
Dragon Sail was esatablished in 2016, directly invested by Guilin Sanjin Pharmaceutical Company Limited and is one of the wholly-owned subsidiaries of Sanjin. The aim of Dragon Sail is to create a high-end monoclonal antibody drug cGMP and commercial manufacturing sites in the Lingang Science Blue Bay (Shanghai ). The total investment of this manufacturing site is around 690 million YUAN . The manufacturing scale of the first phase is 3*2000L and the second phase could reach to 6*2000L scale. Dragon Sail provides one-stop CDMO services for antibody drugs from CMC development to Commercial Production, the site of Blue Bay is one of the largest monoclonal antibody production bases in Shanghai .
Sanyou Biopharmaceuticals Co., Ltd. is a biological high-tech enterprise focusing on R&D and services of innovative antibody drugs. Sanyou is committed to establishing a leading high-quality, high-throughput, integrated R&D and value transformation platform for innovative antibody drugs internationally, constructing a business ecosystem involving therapy, R&D, and diagnostic products and services, and cooperating with global biopharmaceutical, diagnostic, and drug R&D companies to make a new progress in the diagnosis and treatment of human diseases. Sanyou has established an innovative antibody drug integrated R&D laboratory of over 20,000 square meters with advanced facilities and equipment, and more than 40 core innovation technology platforms, including innovative antibody drug discovery featured with a series of trillion phage display antibody libraries, innovative antibody drug optimization, cell line construction, upstream and downstream process development, preclinical R&D and industrial development.
View original content to download multimedia:https://www.prnewswire.com/news-releases/sanyou-biopharmaceuticals-forged-strategic-partnership-with-dragon-sail-pharmaceutical-to-upgrade-integrated-innovative-antibody-drug-rd-301574607.html
As we move toward the end of Q2, it’s time to start thinking about earnings. Looking back at the quarter, analysts are predicting earnings growth of 8%, which may rise to 11% heading into next year. It’s a rosy picture, but it’s also not a sure thing. GDP contracted in Q1, by nearly 1.5%, and some estimates are showing 0% growth in Q2. Such results would meet the technical definition of a recession – and recession is hardly the usual environment to find robust earnings growth. Looking at current
Nuclear submarine supplier to be sold to US buyer after diplomatic row Russian default expected within days Retail sales volumes down 0.5pc in May FTSE 100 rises strongly Ambrose Evans-Pritchard: The pro-Brussels establishment is painting Brexit as an economic disaster to reverse it Sign up here for our daily business briefing newsletter
When you need another stream of income for retirement, you might consider an annuity. You purchase the annuity from an insurance company and receive payments back at a later date. Before buying an annuity, it's important to consider how much … Continue reading → The post How Much Does a $300,000 Annuity Pay Per Month? appeared first on SmartAsset Blog.
A Woman's World reacts to Roe v. Wade overturned
At current levels, investors need a 7% to 8% return just to preserve their wealth.
Tesla plant near Shanghai is going to shut down temporarily, according to reports. On Wednesday, Reuters reported that Tesla (ticker: TSLA) will shut down production in China for a couple of weeks at the start of July to upgrade equipment. Tesla didn’t return a request for comment.
“Time is running out for cash-burning companies kept afloat with easy access to capital,” New Constructs CEO David Trainer said in a Thursday research note.
In this article, we will take a look at 10 value stocks to buy according to billionaire David Tepper. If you want to skip our discussion on Tepper’s history and his hedge fund’s performance, go directly to 5 Value Stocks to Buy According to Billionaire David Tepper. With a net worth of $16.7 billion, David […]
Dividend stocks are the new darlings in S&P 500. But investors are getting burned on those stocks, too.
Peaky Blinders and Cobra producer Joe Donaldson has set an indie, Magic Hour Television, and signed a first-look deal with All3Media International and All3Media-owned drama house New Pictures. Donaldson will develop a slate, funded by All3 and its international arm, and partner with New Pictures co-founder and CEO Willow Grylls to produce scripted TV. Furthermore, Donaldson […]
As Netflix cuts costs to ease subscriber-loss pains, more jobs have been scrapped.
The Dow Jones moved higher as yields fell. Tesla stock skidded after CEO Elon Musk voiced a warning. A Warren Buffett stock rose.
Documentary footage subpoenaed by House Select Committee investigating the Capitol riot
Bitcoin bear markets aren't unusual. But cryptocurrencies have never faced such an aggressive Federal Reserve. Welcome to the crypto ice age.
JPMorgan is getting more optimistic over Advanced Micro Devices’ high-end chip business, citing strong results from the firm’s latest survey of technology buyers. On Thursday, analyst Harlan Sur said the chipmaker’s solid product road map and the firm’s CIO survey suggest the company can achieve 30% to 40% market share in the server processor market over the next few years—up from 20% this year. AMD (ticker: AMD) makes processors that act as the main computing brains for personal computers, servers, and graphics cards.
SEAL Team is expanding its ranks, adding Raffi Barsoumian (Legends of Tomorrow) as a new series regular for Season 6 of the Paramount+ drama. The actor will play Omar, “a Senior Chief with 15 years of experience as a SEAL,” our sister site Deadline reports. “The son of Syrian immigrants, Omar has a deep understanding […]
COMMENT: Royal portraits are usually a disaster, but Jamie Coreth’s painting of the Duke and Duchess makes an intriguing statement about the future of the monarchy, writes Jessie Thompson
Keyshawn Johnson offered a bold prediction this week and said the New York Giants could be this year's Cincinnati Bengals.
Shares in Polestar Automotive Holding UK PLC jumped 16% on their first day of trading Friday, after the Swedish electric-vehicle maker completed a merger with a special-purpose acquisition company amid plans to expand globally. Polestar agreed to be acquired by blank-check company Gores Guggenheim in September. The auto maker is a unit of Volvo Car AB, which in turn is owned by Zhejiang Geely Holding Group Co. of China.
(Bloomberg) -- The S&P 500 Index may have another 24% to fall by year-end, if the past 150 years of financial-market history are any guide.Most Read from BloombergJuul’s Vaping Products Are Ordered Off the Market in the USThese Are the World’s Most Liveable Cities in 2022Elon Musk Says New Tesla Plants Are ‘Money Furnaces’ Losing BillionsRecession Worries Boost Treasuries; Stocks Advance: Markets WrapThe World’s Bubbliest Housing Markets Are Flashing Warning SignsThat’s according to Societe Gene